Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

KALA
Kala Pharmaceuticals Inc
stock NASDAQ

At Close
3/27/2023 3:59:38 PM EDT
15.03USD-3.468%(-0.54)1,012,471
12.02Bid   15.13Ask   3.11Spread IEX
Pre-market
3/27/2023 9:21:30 AM EDT
16.22USD+4.175%(+0.65)0
After-hours
1969-12-31
0.00USD0.000%(0.00)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
30.443M
CEO
Mark Iwicki
Headquarters
Watertown, Massachusetts, USA
Industry
Drug Manufacturers-Specialty & Generic
Next Earnings
2023-05-08 (41d)
Last Split
2022-10-211for50reverse
Related
OMERXLV
KALA Stats
Avg. Vol. 10 Day
349,308
Avg. Vol. 30 Day
1,551,346
Employees
34
Market Cap
30,443,190
Shares Out.
2,025,495
Float
1,576,260
On/Off Exchange
55%/45%
6 Month Beta
0.75
1 Year Beta
0.93
2 Year Beta
0.92
3 Year Beta
0.83
52 Week Low
3.54
52 Week High
93.50
SMA50
14.64
SMA200
12.76
1 Week
-0.79%
1 Month
+48.37%
3 Month
+20.43%
6 Month
+30.70%
1 Year
-82.82%
2 Year
-95.18%
5 Year
-98.16%
Dec 17, 2021
04:01PM EST  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).   GlobeNewswire Inc
Nov 24, 2021
03:03PM EST  Kala Pharma 13D Filing From Mark Blumenkranz Shows Activist Stake On 7.4% In Co.   Benzinga
Nov 18, 2021
04:01PM EST  Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).   GlobeNewswire Inc
Nov 15, 2021
11:11AM EST  Kala Sees Submitting Investigational New Drug Application To FDA For KPI-012; Subject To Regulatory Clearance, Sees Initiating Phase 2/3 Trial For Persistent Corneal Epithelial Defect In Q3'22   Benzinga
11:10AM EST  Kala Pharmaceuticals Q3 EPS $(0.43), Inline, Sales $3.10M Miss $5.16M Estimate   Benzinga
More News
Profile
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.

KALA Stock Summary

Kala Pharmaceuticals Inc (NASDAQ:KALA) stock price today is $15.03, and today's volume is 1,012,471. KALA is down -3.468% today. The 30 day average volume is 1,551,346. KALA market cap is 30.443M with 2,025,495 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC